vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and MAXCYTE, INC. (MXCT). Click either name above to swap in a different company.
Cellectis S.A. is the larger business by last-quarter revenue ($9.5M vs $4.8M, roughly 2.0× MAXCYTE, INC.). MAXCYTE, INC. runs the higher net margin — -200.5% vs -265.9%, a 65.4% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs -20.9%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $-2.9M).
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
CLLS vs MXCT — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $4.8M |
| Net Profit | $-25.3M | $-9.6M |
| Gross Margin | — | — |
| Operating Margin | -181.1% | -234.5% |
| Net Margin | -265.9% | -200.5% |
| Revenue YoY | 375.0% | -20.9% |
| Net Profit YoY | -51.9% | 9.4% |
| EPS (diluted) | $-0.28 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $4.8M | ||
| Q3 25 | — | $4.6M | ||
| Q2 25 | — | $5.8M | ||
| Q1 25 | — | $5.7M | ||
| Q4 24 | — | $6.1M | ||
| Q3 24 | — | $5.6M | ||
| Q2 24 | $9.5M | $5.0M | ||
| Q1 24 | — | $5.6M |
| Q4 25 | — | $-9.6M | ||
| Q3 25 | — | $-12.4M | ||
| Q2 25 | — | $-12.4M | ||
| Q1 25 | — | $-10.3M | ||
| Q4 24 | — | $-10.6M | ||
| Q3 24 | — | $-11.6M | ||
| Q2 24 | $-25.3M | $-9.4M | ||
| Q1 24 | — | $-9.5M |
| Q4 25 | — | -234.5% | ||
| Q3 25 | — | -307.4% | ||
| Q2 25 | — | -244.3% | ||
| Q1 25 | — | -214.1% | ||
| Q4 24 | — | -213.1% | ||
| Q3 24 | — | -250.4% | ||
| Q2 24 | -181.1% | -241.0% | ||
| Q1 24 | — | -219.8% |
| Q4 25 | — | -200.5% | ||
| Q3 25 | — | -269.7% | ||
| Q2 25 | — | -212.2% | ||
| Q1 25 | — | -178.7% | ||
| Q4 24 | — | -175.0% | ||
| Q3 24 | — | -205.9% | ||
| Q2 24 | -265.9% | -188.8% | ||
| Q1 24 | — | -170.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.12 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.11 | ||
| Q2 24 | $-0.28 | $-0.09 | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $103.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $148.6M | $171.5M |
| Total Assets | $407.1M | $202.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $103.0M | ||
| Q3 25 | — | $105.7M | ||
| Q2 25 | — | $126.6M | ||
| Q1 25 | — | $138.3M | ||
| Q4 24 | — | $154.5M | ||
| Q3 24 | — | $153.8M | ||
| Q2 24 | $149.0M | $157.3M | ||
| Q1 24 | — | $157.5M |
| Q4 25 | — | $171.5M | ||
| Q3 25 | — | $180.3M | ||
| Q2 25 | — | $190.7M | ||
| Q1 25 | — | $199.4M | ||
| Q4 24 | — | $206.3M | ||
| Q3 24 | — | $213.3M | ||
| Q2 24 | $148.6M | $221.3M | ||
| Q1 24 | — | $226.4M |
| Q4 25 | — | $202.5M | ||
| Q3 25 | — | $213.5M | ||
| Q2 25 | — | $219.8M | ||
| Q1 25 | — | $230.0M | ||
| Q4 24 | — | $239.5M | ||
| Q3 24 | — | $248.6M | ||
| Q2 24 | $407.1M | $251.5M | ||
| Q1 24 | — | $257.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $-2.7M |
| Free Cash FlowOCF − Capex | $27.6M | $-2.9M |
| FCF MarginFCF / Revenue | 290.5% | -61.0% |
| Capex IntensityCapex / Revenue | 13.2% | 4.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-36.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.7M | ||
| Q3 25 | — | $-7.5M | ||
| Q2 25 | — | $-9.9M | ||
| Q1 25 | — | $-14.4M | ||
| Q4 24 | — | $-7.8M | ||
| Q3 24 | — | $-4.4M | ||
| Q2 24 | $28.9M | $-4.8M | ||
| Q1 24 | — | $-10.6M |
| Q4 25 | — | $-2.9M | ||
| Q3 25 | — | $-7.8M | ||
| Q2 25 | — | $-10.4M | ||
| Q1 25 | — | $-15.1M | ||
| Q4 24 | — | $-8.0M | ||
| Q3 24 | — | $-4.8M | ||
| Q2 24 | $27.6M | $-5.1M | ||
| Q1 24 | — | $-11.4M |
| Q4 25 | — | -61.0% | ||
| Q3 25 | — | -168.5% | ||
| Q2 25 | — | -179.2% | ||
| Q1 25 | — | -262.3% | ||
| Q4 24 | — | -131.6% | ||
| Q3 24 | — | -85.5% | ||
| Q2 24 | 290.5% | -103.3% | ||
| Q1 24 | — | -203.6% |
| Q4 25 | — | 4.8% | ||
| Q3 25 | — | 6.5% | ||
| Q2 25 | — | 10.0% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 7.2% | ||
| Q2 24 | 13.2% | 5.9% | ||
| Q1 24 | — | 14.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLLS
Segment breakdown not available.
MXCT
| Products | $4.2M | 87% |
| Other | $634.0K | 13% |
